# A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

> **NCT06378697** · PHASE3 · COMPLETED · sponsor: **Akeso** · enrollment: 510 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** AK111
- **DRUG:** Placebo+AK111

## Key facts

- **NCT ID:** NCT06378697
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-22
- **Primary completion:** 2025-02-19
- **Final completion:** 2025-11-07
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378697, "A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06378697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*